Assessment of anti-HIV-1 antibodies in oral and nasal compartments of volunteers from 3 different populations

Journal of Acquired Immune Deficiency Syndromes

Volumn 73, Issue 2, 2016, Pages 130-137

  Bergin, Philip J ^a   Langat, Robert ^b   Omosa Manyonyi, Gloria ^b   Farah, Bashir ^b   Ouattara, Gina ^b   Park, Harriet ^c   Coutinho, Helen ^a   Laufer, Dagna ^c   Fast, Pat ^c   Verlinde, Carl ^c   Bizimana, Jean ^d   Umviligihozo, Gisele ^d   Nyombayire, Julien ^d   Ingabire, Rosine ^d   Kuldanek, Kristin ^e   Cox, Josephine ^c   McMorrow, Martin ^a   Fidler, Sarah ^e   Karita, Etienne ^d   Gilmour, Jill ^a,c   Anzala, Omu ^b   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d Project San Francisco   (Rwanda)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; HIV; Mucosal; Nasal; Salivary; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DESCRIPTIVE RESEARCH; ENGLAND; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NASOPHARYNX; NOSE MUCUS; NOSE SMEAR; ORAL BIOPSY; PAROTID GLAND; PILOT STUDY; PRIORITY JOURNAL; RWANDA; SALIVA ANALYSIS; YOUNG ADULT; CASE CONTROL STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LIMIT OF DETECTION; MOUTH; NOSE CAVITY; UNITED KINGDOM; VIROLOGY;

CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; KENYA; LIMIT OF DETECTION; MOUTH; NASAL CAVITY; RWANDA; UNITED KINGDOM;

EID: 84973140858     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001094     Document Type: Article

References (35)

1. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010;464:217-223.
2. Hammer SM, SobieszczykME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369:2083-2092.
3. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010;5:357-361.
4. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infec Dis. 2011;11:507-515.
5. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-1893.
6. Karasavvas N, Billings E, Rao M, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012; 28:1444-1457.
7. Zolla-Pazner S, deCamp A, Gilbert PB, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PloS One. 2014;9:e87572.
8. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38:176-186.
9. Yates NL, Liao HX, Fong Y, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014;6:228-239.
10. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275-1286.
11. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220.
12. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
13. Avdicova M, Crasta PD, Hardt K, et al. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age. Vaccine. 2015;33: 2727-2733.
14. Kaneko H, Bednarek I, Wierzbicki A, et al. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology. 2000;267:8-16.
15. Thomas MA, Song R, Demberg T, et al. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. PloS One. 2013;8:e76344.
16. Excler JL, Parks C, Ackland J, et al. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biological. 2010;38:511-521.
17. Lazarus EM, Otwombe K, Adonis T, et al. Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. PloS One. 2014;9:e112303.
18. Seaton KE, Ballweber L, Lan A, et al. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PloS One. 2014;9:e101863.
19. Esbenshade JC, Edwards KM, Esbenshade AJ, et al. Respiratory virus shedding in a cohort of on-duty healthcare workers undergoing prospective surveillance. Infect Control Hosp Epidemiol. 2013;34:373-378.
20. Omosa-Manyonyi G, Park H, Mutua G, et al. Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya. PloS One. 2014;9:e110228.
21. Hirbod T, Reichard C, Hasselrot K, et al. HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals. Curr HIV Res. 2008;6:28-33.
22. Jaoko W, Karita E, Kayitenkore G, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PloS One. 2010;5:e12873.
23. Keefer MC, Gilmour J, Hayes P, et al. A phase I double blind, placebocontrolled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PloS One. 2012;7:e41936.
24. Cranage MP, Fraser CA, Cope A, et al. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine. 2011;29:1421-1430.
25. Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2015;66:423-437.
26. Scadding GW, Calderon MA, Bellido V, et al. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods. 2012;384:25-32.
27. Ainai A, Tamura S, Suzuki T, et al. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum Vaccines Immunotherapeutics. 2013;9:1962-1970.
28. Rondon C, Romero JJ, Lopez S, et al. Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. J Allergy Clinical Immunology. 2007;119:899-905.
29. Slobod KS, Shenep JL, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine. 2004;22:3182-3186.
30. Fahrbach KM, Malykhina O, Stieh DJ, et al. Differential binding of IgG and IgA to mucus of the female reproductive tract. PloS One. 2013;8: e76176.
31. Domagala A, Kasprzak M, Kurpisz M. Immunological characteristics of cervical mucus in infertile women. Zentralbl Gynakol. 1997;119: 616-620.
32. Lajoie J, Kimani M, Plummer FA, et al. Association of sex work with reduced activation of the mucosal immune system. J Infec Dis. 2014;210: 319-329.
33. Arnold KB, Burgener A, Birse K, et al. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIVsusceptible target cells. Mucosal Immunol. 2016;9:194-205.
34. Birse KD, Cole AL, Hirbod T, et al. Non-cationic proteins are associated with HIV neutralizing activity in genital secretions of female sex workers. PloS One. 2015;10:e0130404.
35. Hasselrot K, Cheruiyot J, Kimani J, et al. Feasibility and safety of cervical biopsy sampling for mucosal immune studies in female sex workers from Nairobi, Kenya. PloS One. 2012;7:e47570.